Ovarian Cancer

Fast track designation was granted by the FDA for pidnarulex in patients with BRCA1/2 or PALB2 mutations with ovarian or breast cancer.

A phase 2/3 trial found that patients with low-grade serous ovarian cancer treated with trametinib had improved survival over the standard of care.

Despite universal recommendations for genetic testing, data indicate that the use of germline testing remained underused among women with ovarian cancer who had commercial insurance.

CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.

Women diagnosed with ovarian cancer were reported to have longer waiting times for treatment vs other cancer types with the exception of kidney cancer.

Patients diagnosed with early-stage ovarian cancer who are treated with novel targeted therapies may experience better overall survival and less financial toxicity compared with those who have late-stage disease.

Philip S. Low, PhD, discusses the obstacles he overcame while creating pafolacianine and what other cancers he hopes will be improved with the use of this agent.

Patients with recurrent ovarian cancer achieved a greater survival benefit after undergoing cytoreductive surgery plus chemotherapy compared with chemotherapy alone.

Encouraging responses and safety data were observed in the phase 3 SORAYA trial, which analyzed mirvetuximab soravtansine monotherapy for patients with folate receptor α–high platinum-resistant ovarian cancer who previously received bevacizumab.

Imaging drug pafolacianine was approved by the FDA to detect ovarian cancer lesions in patients during surgery.

A retrospective study suggests that there might be an association between pre-existing TP53 clonal hematopoiesis of indeterminate potential variants and therapy-related myeloid neoplasms for patients with high-grade ovarian cancer following treatment with rucaparib.

A comparative study indicated that patients with advanced ovarian cancer who received high and low doses of neoadjuvant chemotherapy experienced similar improvements in overall survival.

Patients with platinum-resistant ovarian cancer appear to benefit from treatment with nemvaleukin alfa and pembrolizumab, a combination which was granted a fast track designation for this indication by the FDA.

CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.

Results from the phase 3 NINJA trial indicated that chemotherapy agents such as gemcitabine or pegylated liposomal doxorubicin yielded better survival outcomes vs nivolumab among patients with platinum-resistant ovarian cancer.

Patients previously treated with PARP inhibitors showed an improvement in median progression-free survival when rechallenged with olaparib maintenance.

The topline results from the DeCidE1 trial showing promising results for patients with ovarian cancer treated with maverpopemiut-S.

The folate receptor α–targeting antibody-drug conjugate STRO-002 has a fast track designation from the FDA for advanced, platinum-resistant ovarian cancer following 1 to 3 prior lines of therapy.

The FDA has granted IN10018 a fast track designation for the treatment of patients with platinum-resistant ovarian cancer.

Investigators will continue treating patients with GEN-1 plus neoadjuvant chemotherapy following the results of a pre-planned interim safety review of the phase 1/2 OVATION 2 study.

A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.

Patients with Wilms Tumor-1–positive ovarian cancer have shown promising response to the combination of galinpepimut-s and pembrolizumab.

Data from the phase 3 JAVELIN Ovarian 200 trial indicated that avelumab with or without pegylated liposomal doxorubicin did not yield a significant improvement in overall or progression-free survival over the chemotherapy alone in platinum-resistant/refractory ovarian cancer.

Kathleen Moore, MD, discusses findings compiled from 3 clinical trials of niraparib in patients with ovarian cancer.

The results of a randomized control trial emphasized the need for screening methods earlier in disease but did not show a reduction in deaths for patients with ovarian and tubal cancer.